Introduction: This article discusses the current role of sports practice in people with hemophilia (PWH).
Areas Covered: On 11 January 2025, a bibliographic search was carried out in PubMed using 'hemophilia sports' as keywords. A total of 411 articles were found, of which only 22 were finally analyzed because they were directly related to the title of this article (inclusion criterion). The remaining 389 were eliminated because they were not directly related to the title of the article (exclusion criterion). It was found that sports activity is essential for patients with severe hemophilia to maintain joints' range of motion, diminish joint bleeding, enhance muscle mass and strength, improve proprioception, muscular throphism and bone mineral density, and avert secondary joint degeneration. PWH with factor levels < 10% during sports had a bleeding risk of 41% versus 20% in those with higher factor levels (>10%).
Expert Opinion: Prophylaxis therapy can permit patients with severe hemophilia to participate in vigorous activities or high-impact sports. Moreover, such activities or sports have a positive effect on patient's psychosocial health. Therefore, sports practice should be supported in people with severe hemophilia but patient counseling and tailoring prophylaxis therapy with clotting factors and non-replacement therapy is essential.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/17474086.2025.2459271 | DOI Listing |
Ann Hematol
January 2025
Hemophilia Comprehensive Care Center, Hematology Center, Beijing Key Laboratory of Pediatric Hematology- Oncology, Key Laboratory of Major Diseases in Children, Beijing Children's Hospital, National Key Discipline of Pediatrics (Capital Medical University, Ministry of Education, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Mycoplasma pneumoniae (M. pneumoniae), as one of the susceptible pathogens during childhood, may lead to severe mycoplasmal pneumonia and affect platelet fluctuations. We prospectively collected data on persistent/chronic ITP children who were infected with M.
View Article and Find Full Text PDFJ Pediatr Hematol Oncol
January 2025
Department of Paediatric Haematology, NHS Foundation Trust, Birmingham Children's Hospital, Birmingham, UK.
Objective: Emicizumab promotes efficacious hemostasis in persons with hemophilia A persons with hemophilia A with and without inhibitors. Primary analyses of real-world data and clinical trials have shown emicizumab efficacy and safety; however, long-term data are limited.
Methods: This retrospective study was conducted to assess real-world long-term outcomes of pediatric patients on emicizumab in our hemophilia center between the period of February 2018 and September 2023.
Expert Rev Hematol
January 2025
Department of Physical and Rehabilitation Medicine, Hospital Universitario La Paz, Madrid, Spain.
Introduction: This article discusses the current role of sports practice in people with hemophilia (PWH).
Areas Covered: On 11 January 2025, a bibliographic search was carried out in PubMed using 'hemophilia sports' as keywords. A total of 411 articles were found, of which only 22 were finally analyzed because they were directly related to the title of this article (inclusion criterion).
Regen Ther
March 2025
Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Science, Tehran, Iran.
Gene therapy (GT) as a groundbreaking approach holds promise for treating many diseases including immune deficiencies and blood disorders. GT can benefit patients suffering from these diseases, especially those without matched donors or who are at risk after hematopoietic stem cell transplantation (HSCT). Due to all the advances in the field of GT, its main challenge is still gene delivery.
View Article and Find Full Text PDFThromb Haemost
January 2025
Centre de Ressources et Compétences des Maladies Hémorragiques Constitutionnelles, CHU Clermont-Ferrand, Estaing Hospital, Clermont-Ferrand, France.
Background: The Hemophilia Functional Ability Scoring Tool (Hemo-FAST), consisting of a patient-reported outcome (PRO) part and a clinician-reported outcome (ClinRO) part, was developed as a rapid and effective tool to assess functional mobility in clinical practice. This study (NCT04731701) aimed to validate the psychometric properties of Hemo-FAST for assessment of joint health in people with haemophilia (PwH).
Methods: PwH A or B aged ≥18 years completed questionnaires including the PRO part of Hemo-FAST and the short-form 36 health survey (SF-36) during one study visit.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!